NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced...

Related Keywords

,Stephen Willard ,Nrx Pharmaceuticals ,Source Nrx Pharmaceuticals Inc ,Nasdaq ,Prnewswire Nrx Pharmaceuticals Inc ,Nrx Pharmaceuticals Inc ,Nrxp Nrx Pharmaceuticals ,Suicidal Bipolar Depression ,Chronic Pain ,Chief Executive Officer ,Fast Track Designation ,Breakthrough Therapy Designation ,Special Protocol Agreement ,Biomarker Letter ,Bipolar Depression ,Securities Litigation Reform Act ,Nc ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Biotechnology ,Stock Offering ,